ADHD and Menopause: HRT, Medication and UK Support

Start with the right distinction

Menopause is reached after at least 12 months without a period when hormonal contraception is not affecting bleeding. The time after that point is postmenopause. Symptoms can continue after periods stop.

ADHD is lifelong. Menopause cannot create it, although changing sleep, health, routines and menopause-associated symptoms may make existing difficulties harder to manage.

The current evidence does not support claims that menopause permanently removes a specific "dopamine scaffold", makes ADHD several times worse, or causes a predictable decline in everyone.

Once clinical care is in place, ADHD mentoring may help with practical routines, workload and appointment preparation. It cannot diagnose the cause of symptoms or advise on HRT or ADHD medication.

What menopause can affect

The NHS lists menopause and perimenopause symptoms including:

• hot flushes and night sweats
• difficulty sleeping
• low mood, anxiety or mood changes
• poor memory or concentration
• headaches, palpitations or joint pain
• vaginal and urinary symptoms

Poor sleep can make memory, attention and emotional regulation harder whether or not someone has ADHD.

If periods are still changing, the ADHD and perimenopause guide explains identification and assessment during the transition. The ADHD and hormones guide covers the more limited evidence on menstrual-cycle changes.

What ADHD and menopause research does not yet prove

A 2025 systematic review found only 11 eligible studies on ADHD and sex hormones. The evidence was mainly about puberty and the menstrual cycle, and the authors specifically called for more menopause research.

There is not yet enough evidence to state:

• how often ADHD symptoms worsen after menopause
• whether oestrogen change directly causes a symptom change
• whether HRT improves core ADHD symptoms
• whether ADHD medicine routinely needs a different dose
• that one combined treatment works best

Personal experience is still important. Record the symptom, timing and functional effect, then use it in a clinical review without presenting one mechanism as certain.

HRT and ADHD: what can be said accurately

HRT is an established treatment for several menopause-associated symptoms. NICE recommends individualised discussion of benefits and risks, which vary by age, medical history, whether the person has a uterus, formulation and route.

The NHS HRT guidance explains that HRT can:

• relieve hot flushes and night sweats
• help sleep problems caused by menopause
• help anxiety or low mood caused by menopause
• treat vaginal symptoms
• reduce fragility-fracture risk while it is taken

HRT is not an approved or established treatment for ADHD. If sleep, mood or vasomotor symptoms improve, concentration and day-to-day capacity may improve too. That is not proof that HRT treated the underlying ADHD.

HRT should not be started solely to prevent dementia. NHS guidance says it is not known whether HRT reduces dementia risk.

Benefits and risks are individual

It is also inaccurate to say HRT is simply safe or unsafe for everyone. Current guidance distinguishes:

• combined from oestrogen-only HRT
• tablets from patches, gels or sprays
• personal breast-cancer and blood-clot risk
• age and time since menopause
• whether the person has a uterus

A GP, prescribing nurse or menopause specialist can use the NICE discussion aid to explain relevant absolute risks. If treatment does not help, side effects continue or the situation is complex, NICE recommends referral to someone with menopause expertise.

HRT reviews

NICE recommends reviewing treatment at three months for effectiveness and tolerability, then annually unless an earlier review is clinically needed.

Keep a note of:

• which symptoms HRT is intended to treat
• the formulation and dose
• benefits and side effects
• any unexpected bleeding
• the next review date

Report postmenopausal bleeding or unexpected bleeding while using HRT to a GP rather than assuming it is harmless.

Coordinating HRT and ADHD medication

Do not adjust either treatment because one feels less effective.

Give the menopause clinician, GP, pharmacist and ADHD prescriber the same current list of:

• prescribed medicines and formulations
• non-prescribed medicines and supplements
• doses and timing
• side effects
• relevant blood-pressure, pulse and weight monitoring

NICE says ADHD medication should be initiated and monitored by clinicians with appropriate expertise. A review may consider adherence, sleep, mood, cardiovascular measurements, other medicine changes and functional benefit. A standard menopause-related dose increase is not recommended.

Useful questions include:

1. Which symptoms is each treatment expected to improve?
2. What monitoring does each medicine require?
3. Could a side effect be contributing to sleep, mood or concentration problems?
4. Who should make changes and inform the other prescriber?
5. When will treatment benefit be reviewed?

Memory problems deserve a proper assessment

Brain fog and memory difficulty are recognised menopause symptoms. They should not automatically be labelled ADHD or dismissed as normal ageing.

Speak to a GP if cognitive changes are:

• sudden or rapidly worsening
• progressive rather than variable
• affecting familiar daily tasks
• accompanied by neurological symptoms
• causing concern to you or people close to you

ADHD assessment looks for symptoms beginning in childhood and persisting across settings. A new problem after menopause does not meet that requirement by itself.

If a lifelong pattern may have been missed, read ADHD diagnosis in women and what happens in an ADHD assessment. A trained specialist should also consider sleep, mood, medicine effects and physical health.

Practical changes that do not depend on a diagnosis

Use one external memory system

Choose one calendar and one task list. Put appointment instructions and medicine review dates in the same place. The ADHD and working-memory guide offers ways to reduce recall demands.

Protect sleep through clinical and practical care

Discuss persistent night sweats, insomnia or sleep apnoea symptoms with a clinician. Use general sleep routines as support, not as a substitute for treating the cause. See ADHD and sleep.

Request workplace support

Concentration, memory, temperature and fatigue symptoms may affect work. Depending on the circumstances, useful changes might include written instructions, fewer interruptions, flexible breaks or a cooler work area. Read the guide to reasonable adjustments for ADHD and discuss the actual barriers with the employer.

Reduce competing demands

Automate routine payments, reduce duplicate lists and delegate clearly defined tasks. If exhaustion and loss of functioning are persistent, consider whether ADHD burnout, depression or another health condition also needs assessment.

Maintain health reviews

Keep up with nationally recommended screening and discuss bone, cardiovascular, sexual and urinary health with the appropriate clinician. Mentoring should never replace these reviews.

Where mentoring fits

ADHD mentoring cannot prescribe, assess cognition, recommend HRT or decide whether ADHD medication should change. With clinical questions directed to the right professionals, it may help you:

• prepare concise appointment notes
• implement external memory systems
• simplify household or work routines
• turn agreed adjustments into practical steps
• review which systems are reducing daily friction

If that non-clinical support fits your plan, you can book a free 15-minute discovery call. Take new, severe or unexplained health symptoms to a GP or relevant specialist.

Key points

• Menopause does not cause ADHD.
• ADHD-specific menopause evidence remains limited.
• HRT treats menopause-associated symptoms, not established core ADHD.
• HRT benefits and risks must be individualised.
• Coordinate the full medicine list between menopause and ADHD prescribers.
• New or progressive cognitive change needs medical assessment.
• Mentoring can support practical implementation but not clinical treatment.

This article was source-checked on 29 July 2026 against current NHS and NICE guidance and a 2025 systematic review. It is general information and has not been reviewed by a menopause specialist, gynaecologist, pharmacist or ADHD prescriber.